TNG 260
Alternative Names: TNG-260Latest Information Update: 22 Jun 2023
At a glance
- Originator Tango Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase and corepressor complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 12 Jun 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in USA (PO) (NCT05887492)
- 09 May 2023 TNG 260 receives fast track status for Non small cell lung cancer (Combination therapy, Second-line therapy or greater and late-stage disease ) in USA
- 18 Apr 2023 Pharmacodynamics data from preclinical studies in Cancer released by Tango Therapeutics